Manifestation eines Diabetes mellitus unter Therapie mit Olanzapin

 

 Buy Article Permissions and Reprints

Zusammenfassung

Eine potenzielle Nebenwirkung der Olanzapintherapie ist die Manifestation eines Diabetes mellitus. Mögliche pathogenetische Mechanismen werden diskutiert, wobei der Minderung der Insulinempfindlichkeit infolge einer Gewichtszunahme entsprechend der Datenlage die größte Relevanz zukommt.

Abstract

A potential side-effect in the treatment with olanzapine is hyperglycemia or new onset diabetes mellitus. There are possible mechanisms by which olanzapine could interfere with glucose metabolism but decreased insulin sensitivity due to weight gain is of most relevance.

Literatur

• 1 Smith H, Kenney-Herbert J, Knowles L. Clozapine-induced diabetic ketoacidosis.  Austr New Zealand J Psych. 1999;  33 120-121
  PubMedGoogle Scholar
• 2 Colli A, Cocciolo M, Francobandiera G, Rogantin F, Cattalini N. Diabetic ketoacidosis associated with clozapine treatment.  Diabetes Care. 1999;  22 176-177
  PubMedGoogle Scholar
• 3 Pierides M. Clozapine monotherapy and ketoacidosis.  Br J Psychiatry. 1997;  171 90-91
  PubMedGoogle Scholar
• 4 Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment.  Diabetes Care. 1999;  22 1002-1003
  PubMedGoogle Scholar
• 5 Hauptmann B, Kupsch A, Arnold G. Hyperglycemia associated with low-dose clozapine treatment.  J Neural Transm. 1999;  106 XII
  PubMedGoogle Scholar
• 6 Fertig M K, Brooks V G, Shelton P S, English C W. Hyperglycemia associated with olanzapine.  J Clin Psychiatry. 1998;  59 687-689
  PubMedGoogle Scholar
• 7 Hayek D, Hüttl V, Reiss J, Schweiger H D, Füeßl H S. Hyperglykämie und Ketoazidose unter Olanzapin.  Nervenarzt. 1999;  70 836-837
  CrossrefPubMedGoogle Scholar
• 8 Lindenmayer J P, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus.  Am J Psychiatry. 1999;  156 1471
  PubMedGoogle Scholar
• 9 Goldstein L E, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey G K, Sachs G, Stern T A. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment.  Psychosomatics. 1999;  40 438-443
  PubMedGoogle Scholar
• 10 Selva K A, Scott S M. Diabetic ketoacidosis associated with olanzapine in an adolescent patient.  J Pediatr. 2001;  138 936-938
  CrossrefPubMedGoogle Scholar
• 11 Wirshing D A, Spellberg B J, Erhart S M, Marder S R, Wirshing W C. Novel antipsychotics and new onset diabetes.  Biol Psychiatry. 1998;  44 778-783
  CrossrefPubMedGoogle Scholar
• 12 Ober S K, Hudak R, Rusterholz A. Hyperglycemia and olanzapine.  Am J Psychiatry. 1999;  156 970
  PubMedGoogle Scholar
• 13 Roefaro J, Mukherjee S M. Olanzapine-induced hyperglycemic nonketotic coma.  Ann Pharmacother. 2001;  35 300-302
  CrossrefPubMedGoogle Scholar
• 14 Naber D, Lambert M, Krausz M, Haasen C. Atypische Neuroleptika in der Behandlung schizophrener Patienten. Bremen; UNI-MED 2000
  Google Scholar
• 15 Howarth P, Emanuel M, Holgate S. Astemizole, a potent histamine H1 receptor antagonist: effect on allergic rhinoconjunctivitis, on antigen and histamine induced skin response and relationship to serum levels.  Br J Clin Pharmacol. 1984;  18 1-8
  PubMedGoogle Scholar
• 16 Wilson J D, Hillas S L. Astemizole: a new long-acting antihistamine in the treatment of seasonal allergic rhinitis.  Clin Allergy. 1983;  13 131-140
  PubMedGoogle Scholar
• 17 Melkersson K, Hulting A L, Brismar K E. Elevated levels of insulin, leptin, and lipids in olanzapine-treated patients with schizophrenia or related psychosis.  J Clin Psychiatry. 2000;  61 742-749
  PubMedGoogle Scholar
• 18 Seaburg H L, McLendon B M, Doraiswamy P M. Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature.  Pharmacotherapy. 2001;  21 1448-1454
  CrossrefPubMedGoogle Scholar
• 19 Lindenmayer J P, Nathan A M, Smith R C. Hyperglycemia associated with the use of atypical antipsychotics.  J Clin Psychiatry. 2001;  62 30-38
  CrossrefPubMedGoogle Scholar
• 20 Knauf H. Nebenwirkungen der Diuretika.  Nieren- und Hochdruckkrankheiten. 1996;  4 184-191
  PubMedGoogle Scholar
• 21 Langford H G, Cutter G, Oberman A, Kansal P, Russell G. The effect ot thiazide therapy and cholesterol metabolism and of glucose on potassium: results of a cross-sectional study in patients from the Hypertension Detection and Follow-up Program.  J Hum Hypertension. 1990;  4 491-500
  PubMedGoogle Scholar

Dr. Ralf Kozian

Landesklinik Brandenburg

Anton-Saefkow-Allee 2

14772 Brandenburg